US, India and five other nations talk post-covid trade

BRIC Targets USD 300 Billion Indian Bioeconomy by 2030 and USD 1 Trillion by 2047

Established under the Department of Biotechnology (DBT), BRIC represents an integrated institutional framework designed to bring multiple autonomous biotechnology research institutions under a coordinated structure. The initiative seeks to improve scientific collaboration, encourage multidisciplinary research and enable institutions to share infrastructure and resources while retaining their individual scientific capabilities.

India has set its sights on expanding its biotechnology economy to USD 300 billion by 2030 and USD 1 trillion by 2047, with the Biotechnology Research and Innovation Council (BRIC) expected to play a central role in accelerating scientific innovation, research commercialisation and industrial development. Union Minister of State (Independent Charge) for Science and Technology Dr. Jitendra Singh announced these ambitions while addressing the Fourth Annual General Meeting of the BRIC Society in New Delhi on 21 November 2026.

The Minister highlighted the importance of integrating India’s biotechnology research institutions, strengthening institutional collaboration and creating stronger connections between scientific discoveries and industrial applications. He noted that India’s bioeconomy has expanded from approximately USD 10 billion to more than USD 195 billion, reflecting the growing contribution of biotechnology to healthcare, agriculture, manufacturing and other strategic sectors.

BRIC’s Integrated Research Model Strengthens Institutional Collaboration

Established under the Department of Biotechnology (DBT), BRIC represents an integrated institutional framework designed to bring multiple autonomous biotechnology research institutions under a coordinated structure. The initiative seeks to improve scientific collaboration, encourage multidisciplinary research and enable institutions to share infrastructure and resources while retaining their individual scientific capabilities.

Addressing the AGM, Dr. Jitendra Singh described BRIC as one of the Government of India’s early initiatives in institutional integration within the scientific research ecosystem. He observed that its collaborative approach to governance and research has subsequently influenced similar institutional arrangements across other government organisations.

The Fourth Annual General Meeting, held at Kartavya Bhawan in New Delhi under the chairmanship of Dr. Jitendra Singh, reviewed BRIC’s institutional development, scientific achievements, governance reforms, research collaborations and future priorities. Dr. Rajesh S. Gokhale, Secretary of the Department of Biotechnology and Director General of BRIC, presented an overview of the Council’s activities and achievements.

BRIC’s Research Performance and Emerging Scientific Capabilities

The Minister highlighted BRIC’s research performance, noting that its institutions had secured the first position among government institutions in health sciences and second position in biological sciences in India for the second consecutive year, according to the Nature Index India.

He emphasised that scientific achievements must extend beyond research publications and patents to generate technologies, products and solutions that address practical challenges. Research programmes across BRIC institutions cover several important areas, including novel therapeutics, advanced diagnostics, disease detection, animal health, climate-resilient agriculture, advanced materials and sustainable biomaterials.

These research capabilities provide opportunities to address national priorities in healthcare, food security, agricultural productivity and industrial development. Greater coordination between research institutions can also help reduce duplication of scientific infrastructure and improve access to specialised facilities.

Accelerating the Journey from Laboratory Research to Commercial Products

A major priority identified during the meeting was the need to accelerate research translation and strengthen partnerships between scientific institutions, entrepreneurs, investors and industry. Dr. Jitendra Singh called for industrial participation at the early stages of technology development so that researchers can better understand commercial requirements, regulatory pathways and potential applications.

He stressed that taking scientific discoveries from laboratories to the marketplace requires access to capital, mentorship, industry partnerships and technology development infrastructure. Research commercialisation should become a natural extension of India’s scientific ecosystem, enabling discoveries to progress into startups, industrial products and commercially viable technologies.

The Minister also highlighted initiatives such as BRIC’s Entrepreneur-in-Residence programme and collaborations supporting biomanufacturing, technology scale-up and commercialisation. These programmes are intended to strengthen the connection between publicly funded research and the emerging biotechnology industry.

India’s Biotechnology Startup Ecosystem Expands

India’s biotechnology startup ecosystem has grown to more than 11,000 startups, reflecting the increasing participation of entrepreneurs and technology developers in the sector. Dr. Jitendra Singh encouraged BRIC institutions to provide greater opportunities for young scientists and innovators to move beyond academic research towards product development, technology translation and enterprise creation.

The growing startup ecosystem creates opportunities across biopharmaceuticals, diagnostics, agricultural biotechnology, industrial biotechnology, bio-based materials and other emerging fields. Stronger collaboration between research institutions and startups can help convert scientific discoveries into technologies with commercial and societal applications.

The Minister also highlighted the importance of attracting Indian scientific talent working overseas and connecting international researchers with domestic research opportunities. Suggestions discussed during the AGM included greater use of platforms such as Vaibhav Connect to facilitate engagement between the scientific diaspora and BRIC institutions.

BioE3 Challenge Encourages Young Biotechnology Innovators

The D.E.S.I.G.N. for BioE3 Challenge was another initiative highlighted during the meeting. According to the Minister, the programme had received more than 6,000 proposals from school students and citizens across its two categories, demonstrating growing interest in biotechnology innovation among young people and the wider public.

The initiative provides an opportunity to encourage early engagement with biotechnology and develop innovative ideas addressing emerging scientific and societal challenges. Dr. Jitendra Singh urged BRIC to continue nurturing young talent, attracting promising researchers and promoting interdisciplinary research.

He also emphasised the importance of communicating scientific achievements in accessible formats so that the public can better understand the relevance of research and its potential benefits.

Strengthening BRIC’s Governance and Research Infrastructure

The AGM reviewed several measures aimed at strengthening BRIC’s institutional and administrative capabilities. These included the operationalisation of its Secretariat and efforts to reinforce scientific research capacity through recruitment against revived scientific positions.

The meeting also witnessed the release of the BRIC Handbook of Memorandum of Association, Rules, Regulations and Bye-laws. The handbook provides a consolidated reference for the Council’s governance structure and institutional functioning.

Members were additionally apprised of the proposal concerning the dissolution of existing societies of constituent autonomous institutions and their merger with BRIC as part of the ongoing institutional restructuring process. This proposal forms part of the broader effort to establish a coordinated framework for biotechnology research institutions.

India’s Bioeconomy Vision: USD 300 Billion by 2030 and USD 1 Trillion by 2047

The targets of a USD 300 billion bioeconomy by 2030 and USD 1 trillion by 2047 represent the scale of India’s biotechnology ambitions over the coming decades. Achieving these objectives will require progress across research and development, biomanufacturing, biotechnology startups, industrial applications and the commercialisation of indigenous technologies.

BRIC’s integrated research framework offers a platform for strengthening collaboration between scientific institutions and industry. Its work across healthcare, agriculture, advanced materials, diagnostics and biological sciences can contribute to the development of technologies addressing both domestic requirements and international markets.

India’s expanding biotechnology research capabilities, growing startup ecosystem and increasing emphasis on biomanufacturing provide a foundation for the next phase of development. By connecting scientific institutions with entrepreneurs, investors and industrial partners, BRIC is positioned to contribute to the transformation of India’s research capabilities into globally competitive biotechnology products and solutions.

As India advances towards its 2047 development vision, biotechnology will remain an important contributor to healthcare innovation, agricultural resilience, sustainable manufacturing and high-value industrial growth. The expansion of BRIC’s collaborative research model, combined with stronger industry participation and opportunities for young scientists, will support India’s ambition to emerge as a major global biotechnology and bioeconomy hub.